References Injectable Drug Delivery Devices Global Market Report 2021: COVID-19 Growth and Change to 2030, ResearchandMarkets.com, March 21, 2021, Drug Delivery Devices Global Market Report 2021: COVID-19 Implications and Growth to 2030, ResearchAndMarkets, Aug
It is administered once weekly via subcutaneous injection and is being researched in late-stage trials for obesity and type 2 diabetes, but it is not yet approved
Oral semaglutide and cardiovascular outcomes in high-risk type 2 diabetes
The dose-response curve for Retatrutide is linear: 1mg (8.7% loss), 4mg (15.2%), 8mg (21.1%), 12mg (24.2%)
While heterogeneity and limited study numbers warrant caution, these results highlight GLP-1RAs as promising candidates for AUD management